A study by Department of Energy researchers detailed a potential method to detect the novel coronavirus
Research teams from the Department of Energy’s Oak Ridge National Laboratory and their technologies have received seven 2021 R&D 100 Awards, plus special recognition for a COVID-19-related project.
Staff at Oak Ridge National Laboratory organized transport for a powerful component that is critical to the world’s largest experiment, the international ITER project.
Four first-of-a-kind 3D-printed fuel assembly brackets, produced at the Department of Energy’s Manufacturing Demonstration Facility at Oak Ridge National Laboratory, have been installed and are now under routine operating
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Deborah Frincke, one of the nation’s preeminent computer scientists and cybersecurity experts, serves as associate laboratory director of ORNL’s National Security Science Directorate. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy
At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.
The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.
When COVID-19 was declared a pandemic in March 2020, Oak Ridge National Laboratory’s Parans Paranthaman suddenly found himself working from home like millions of others.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.